This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Teresa Vicente, MD; Arturo Ortega, MD; Patricia Muñoz, M; M. Dolores Diaz; Emilio Bouza, MD
Madrid, Spain

Arch Intern Med. 1993;153(4):534.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In a previous article,¹ we described two patients with acquired immunodeficiency syndrome with Mycobacterium avium complex (MAC) bacteremia, prolonged fever, and weight loss, refractory to standard therapy, who responded to the administration of thalidomide. The activity of thalidomide was probably related to its immunomodulatory effect; it is not unusual to exclude activity of the drug against MAC.

To ascertain the potential effectiveness of thalidomide against MAC, we tested its "in vitro" activity against 36 different MAC strains by the agar dilution method.^2,3 A 10⁴-µg/mL stock solution was prepared using dimethylformamide as a solvent. Afterward, serial twofold dilutions were made in sterile distilled water and incorporated into an agar with a pH of 6.8 (7H10 Middlebrook) to obtain the following final concentrations: 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, and 0.5 µg/L, respectively. Inocula were prepared from every strain growth on Löwenstein-Jensen media in . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?